Pyxis Oncology, Inc. (PYXS): M&A transaction — Pyxis Oncology completes all-stock acquisition of Apexigen for ~$10.7M

Pyxis Oncology, Inc.

Pyxis issued ~4.3M shares (exchange ratio 0.1725) so Apexigen holders own ~10% of combined co.
Acquisition adds clinically validated APXiMAB antibody-discovery platform and Phase 2 CD40 agonist sotigalimab (now PYX-107).
Combined co. positions for next-gen ADC creation; cash runway extended into 1H 2025.
Jakob Dupont, former Apexigen director, appointed to Pyxis board as independent Class III director.
Development strategy and timelines for PYX-107 to be shared in 4Q23.

item 2.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jakob Dupont

Director

PYXS · Pyxis Oncology, Inc.

Effective: 2023-08-23
Filed: August 23, 2023, 7:59 PM ET

On August 23, 2023, effective as of the Effective Time, Jakob Dupont, M.D., a former director of Apexigen, was appointed to the Board as a Class III director and his term will expire at the annual meeting of stockholders to be held in 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jakob Dupont was appointed as Director at Pyxis Oncology, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 23, 2023, effective as of the Effective Time, Jakob Dupont, M.D., a former director of Apexigen, was appointed to the Board as a Class III director and his term will expire at the annual meeting of stockholders to be held in 2024.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Pyxis Oncology, Inc. completed an acquisition involving Apexigen, Inc. for all-stock transaction valued at approximately $10.7 million (closed 2023-08-23).

Action: acquisition
Counterparty: Apexigen, Inc.
Consideration: all-stock transaction valued at approximately $10.7 million
Closing: 2023-08-23

Exact text from the filing

clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million. The combined company is positioned at the forefront of ADC innovation with a platform that now includes four key components: novel humanized antibody generation capabilities, an

View on SEC.gov

Browse all m&a transactions →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-044036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.